Blueprint library/PC

Pharmaceutical Process Characterization Software

Risk question to designed study. Experimental result to proven range. Every control-strategy decision retains its evidence.

Manage process characterization strategy, prior knowledge, risk assessments, DoE and edge-of-failure studies, parameter-to-quality relationships, scale and platform models, proven ranges, design-space claims, control-strategy decisions, and validation handoff.

Pharmaceutical Process Characterization Software

Process characterization turns development knowledge into defensible operating boundaries and controls. The hard part is not storing study reports. It is preserving why a factor was studied, which materials and scales the result covers, how analysis produced a relationship, and where that relationship is safe to reuse.

Seal connects prior knowledge, risk questions, study design, execution, samples, source data, models, proven ranges, control-strategy decisions, validation requirements, and later commercial evidence.

The characterization strategy starts with decisions

Product and process understanding, modality, unit operations, scale path, material variability, prior knowledge, regulatory strategy, development stage, intended commercial configuration, known failure modes, and uncertainty define the strategy.

Each study exists to support a decision: classify a parameter, establish a range, test robustness, confirm a model, define a control, or bound a residual risk.

Platform knowledge has applicability rules

Platform, product family, molecule attributes, expression or synthesis route, unit operation, resin or equipment class, scale, material properties, process mode, site, and historical performance define where prior knowledge can apply.

Platform knowledge inherited only where applicability and product-specific evidence support it
Fig. 1 / Platform knowledge inherited only where applicability and product-specific evidence support it

Reuse records the source studies, differences, assumptions, exclusions, uncertainty, reviewer, and approval. It never turns similarity into an unsupported universal claim.

Risk assessment becomes a question register

Hazard, failure mode, process input, material attribute, parameter, quality attribute, detectability, prior evidence, uncertainty, proposed study, priority, and control implication remain connected.

Risk scores can change; the scientific question and evidence path remain stable and reviewable.

Parameters and attributes are governed concepts

Name, definition, unit, calculation, sampling or measurement point, process phase, source, expected range, transformation, directionality, criticality hypothesis, and version prevent one team’s “temperature” from being treated as another team’s equivalent measurement.

Study design preserves experimental intent

Objective, hypothesis, factors, levels, responses, design type, blocks, randomization, replicates, center points, controls, scale, materials, equipment, analytical methods, run order, power or precision basis, exclusion rules, and acceptance criteria define the design.

Protocol amendments retain why the design changed and which planned analyses remain valid.

Study execution captures actual conditions

Run genealogy, material lots, equipment, recipe, actual factor settings, time-series context, additions, holds, interventions, alarms, observations, samples, deviations, and completion state remain part of the study record.

Nominal factor settings never replace what actually occurred.

Analytical results remain tied to process time

Sample identity, process position, collection time, preparation, method version, instrument, source file, suitability, result, validity, repeat, and final value connect each response to the exact experimental run and conditions.

Data exclusions require a scientific record

Missing data, failed runs, analytical invalidations, protocol deviations, equipment faults, outliers, transformation choices, and excluded observations retain original values, rationale, approver, analysis impact, and alternate result where applicable.

The final model never conceals the path from raw population to analyzed population.

Models are versioned claims

Inputs, responses, coding, interactions, transformations, algorithm, software, fit, residuals, diagnostics, prediction interval, uncertainty, applicability, validation, version, and reviewer define the model.

Unit-operation models assembled from governed studies, applicability boundaries, and product-specific confirmation
Fig. 2 / Unit-operation models assembled from governed studies, applicability boundaries, and product-specific confirmation

A statistically significant term is not automatically scientifically meaningful or suitable as a control.

Parameter-to-quality relationships retain strength

No observed relationship, weak association, monotonic effect, interaction, threshold, edge of failure, mechanistic link, and uncertain relationship remain distinct conclusions with cited studies and model versions.

Direction, magnitude, confidence, process region, material and scale limitations, and affected CQAs travel with the relationship.

Proven acceptable ranges are evidence objects

Nominal setpoint, explored range, proven range, proposed operating range, edge-of-failure boundary, uncertainty reserve, scale allowance, material restrictions, linked CQAs, and control response define each range.

The system distinguishes what was explored, what was shown acceptable, and what is selected for routine operation.

Design-space claims preserve multidimensional boundaries

Factors, interactions, response constraints, probability or confidence basis, model version, material and scale assumptions, visualization, verification data, filing state, and change implications define the claim.

A rectangular operating range cannot silently replace a coupled multidimensional relationship.

Control strategy resolves each risk

Input-material control, parameter control, in-process test, feedback or feed-forward control, equipment capability, procedural control, release test, monitoring, and residual risk connect to the relationship and evidence they address.

Controls are proposed, verified, approved, implemented, and lifecycle monitored as distinct states.

Scale models separate geometry from evidence

Mixing, mass transfer, heat transfer, shear, residence time, load density, flux, pressure, path length, hold volume, equipment design, process dynamics, and model assumptions define scale translation.

Small-scale model qualification records which commercial phenomena it reproduces, which it does not, and the evidence supporting that conclusion.

The validation handoff is explicit

Selected CPPs, IPCs, CQAs, operating ranges, sampling positions, statistical expectations, challenge conditions, enhanced monitoring, residual risks, and commitments become traceable PPQ requirements.

Validation can show which characterization claim each criterion is intended to confirm.

Commercial evidence can strengthen or challenge knowledge

PPQ, continued verification, deviations, changes, complaints, stability, material trends, and site transfers feed back into relationships and applicability.

Contradictory evidence opens reassessment; it does not overwrite the original approved conclusion.

Portfolio learning is governed reuse

Cross-product evidence can identify recurring unit-operation behavior and useful starting points, but reuse always preserves product, material, process, scale, site, method, and time boundaries.

The next program starts with a qualified baseline and a visible delta, not a blank page or an unreviewed historical average.

Where Seal is strongest

Seal is strongest at the junction of development execution, analytical results, risk management, statistical modeling, control strategy, validation, CMC, and lifecycle knowledge. It owns the relationship from question to evidence to operating decision.

Prove one consequential unit operation end to end

The first implementation should follow one unit operation from prior knowledge and risk assessment through designed experiments, actual runs, analytical responses, an excluded observation, final model, proven range, parameter classification, control strategy, PPQ requirement, and later commercial signal.

Include a material-lot interaction, one failed experimental run, a model revision, an edge-of-failure result, a platform claim accepted with restrictions, and a commercial trend that narrows applicability. The system must preserve both what is known and where it stops being known.

Capabilities

01Characterization Strategy & Question Register
Product, process, platform, development stage, risks, unknowns, study questions, priorities, decisions, owners, dependencies, and approval state stay governed.
02Prior-Knowledge Applicability
Source products, studies, materials, unit operations, scales, relationships, similarities, differences, assumptions, restrictions, confirmation, and reviewer decision define safe reuse.
Objectives, hypotheses, factors, levels, responses, blocks, run order, materials, equipment, actual conditions, samples, deviations, exclusions, and approvals remain connected.
Samples, process positions, method versions, instruments, source files, suitability, results, repeats, invalidations, final values, and review feed the study without manual reconciliation.
05Parameter-to-Quality Relationship
Parameters, CQAs, interactions, direction, magnitude, thresholds, edge evidence, model version, confidence, material and scale boundaries, and conclusion remain one reusable knowledge object.
06Proven Range & Design-Space Claim
Explored, proven and selected operating regions, multidimensional constraints, assumptions, uncertainty, verification, scale allowance, filing state, and evidence stay distinct and traceable.
Material controls, CPPs, IPCs, equipment capability, procedural controls, monitoring, release tests, verification, residual risk, and rationale connect directly to characterized relationships.
Selected parameters, attributes, ranges, sampling, challenge conditions, statistical expectations, residual risks, enhanced monitoring, and commitments become PPQ requirements and receive later commercial evidence.

Entities

Entity hierarchy
What it records
Kind
Characterization Strategy
Product, process, stage, prior knowledge, risk questions, study plan, decisions, roles, and state.
entity
Platform Knowledge
Product family, unit operation, reusable relationship, source evidence, boundaries, uncertainty, and approval.
entity
Characterization Question
Risk, input, parameter, CQA, hypothesis, uncertainty, proposed evidence, priority, and decision.
entity
Process Parameter
Definition, unit, phase, source, range, transformation, hypothesis, criticality, and version.
entity
Quality Attribute
Definition, method, unit, acceptance, clinical or process relevance, and lifecycle state.
entity
Characterization Study
Objective, design, factors, responses, runs, materials, scale, methods, criteria, and approvals.
entity
Multivariate Characterization Study
DoE factors, levels, responses, blocks, randomization, replicates, analysis, ranges, and decisions.
template
CHAR-AEX-014-v04
AEX load, pH and conductivity study with a material-lot interaction.
record
Characterization Run
Study, run order, actual conditions, materials, equipment, execution, samples, deviations, and state.
entity
Characterization Experimental Run
Actual factors, materials, equipment, sequence, observations, samples, exceptions, and completion.
template
RUN-AEX-014-026
Edge-of-failure run excluded from the primary model after a confirmed equipment fault.
record
Characterization Response
Run, sample, CQA, method, source data, value, validity, exclusion, and final analysis state.
entity
Characterization Model
Dataset, factors, responses, interactions, method, fit, diagnostics, uncertainty, applicability, and version.
entity
Response-Surface Model
Coded factors, interactions, transformations, fit, diagnostics, prediction, uncertainty, and applicability.
template
MODEL-AEX-PURITY-v06
Approved purity model retaining a resin-lot restriction and revised residual treatment.
record
Parameter–Quality Relationship
Parameter, CQA, direction, magnitude, interaction, boundary, confidence, evidence, and conclusion.
entity
Proven Acceptable Range
Explored, proven and operating ranges, edge, uncertainty, scale, material limits, and evidence.
entity
Parameter Proven-Range Assessment
Explored region, acceptable results, edge evidence, uncertainty, scale allowance, and operating selection.
template
PAR-AEX-PH-v03
Proven pH range with narrower routine operation selected for robustness.
record
Design-Space Claim
Factors, response constraints, model, multidimensional boundary, assumptions, verification, and filing state.
entity

FAQ

It connects characterization strategy, prior knowledge, risk questions, designed studies, actual experimental runs, analytical responses, models, parameter-quality relationships, proven ranges, design-space claims, control strategy, validation requirements, and lifecycle evidence.
Yes, through an applicability assessment that preserves source studies, product and process similarities, meaningful differences, materials, scale, equipment, assumptions, uncertainty, restrictions, confirmation, and approval.
It governs objective, hypothesis, factors, levels, responses, design, blocks, randomization, replicates, run order, actual execution, deviations, analytical results, exclusions, model versions, diagnostics, and conclusions. Specialized statistics can still run in validated external tools.
Original observations remain. Any invalidation or exclusion records the event, scientific rationale, approver, analysis impact, population version, and alternate analysis where applicable.
The explored range records where experiments were run. The proven range records the region supported by acceptable evidence. The selected operating range is the approved routine region and may be intentionally narrower.
Yes. Factors, interactions, response constraints, model and dataset versions, uncertainty, material and scale assumptions, verification, approval and filing state remain connected.
Each material or parameter control references the risk and characterized relationship it addresses, along with verification evidence, residual risk, implementation state and lifecycle monitoring.
Approved CPPs, IPCs, CQAs, ranges, sampling positions, challenge conditions, statistical expectations, residual risks and commitments become traceable validation requirements.
It can trigger reassessment. PPQ, CPV, deviations, changes, complaints and trends are attached as later evidence; a revised conclusion is versioned without overwriting the original approved basis.
Prove one unit operation from prior knowledge and risk question through DoE execution, analytical responses, an exclusion, final model, proven range, control decision, PPQ handoff, and a later commercial signal that changes applicability.

Related blueprints

biotech

Biotech Startup R&D, Quality & Manufacturing Software

Connect ELN, inventory, samples, process and analytical development, QMS, tech transfer, CDMO oversight, and CMC evidence as a biotech program moves toward GMP.

msat

MSAT Process Knowledge & Manufacturing Support Software

Run Manufacturing Science and Technology across process ownership, technology transfer, site and product knowledge, batch monitoring, process signals, investigations, change impact, validation and CPV, improvement, comparability, commitments, and governed manufacturing support.

E&L

Pharmaceutical Extractables & Leachables (E&L) Management Software

Map product-contact systems, characterize materials, plan extractables and leachables studies, calculate exposure and analytical evaluation thresholds, identify compounds, govern toxicological assessments, justify bracketing, and manage lifecycle change.

Nitrosamines

Pharmaceutical Nitrosamine Risk Assessment & Control Software

Govern product and API nitrosamine risk assessments, amine and nitrosating-agent knowledge, formation pathways, acceptable-intake limits, confirmatory methods and testing, mitigation, stability, supplier dependencies, regulatory reporting, and lifecycle review.

Viral Safety

Biologics Viral Safety & Viral Clearance Management Software

Govern biologics viral safety strategies, source and cell-substrate risk, virus testing, adventitious-agent methods, scaled-down clearance models, spiking studies, log-reduction calculations, step and process claims, lifecycle changes, and batch-release dependencies.

PAT / RTRT

Pharmaceutical PAT & Real-Time Release Testing Software

Govern PAT methods, sensors, chemometric models, calibration sets, predictions, process actions, model lifecycle, RTRT strategies, fallback testing, and batch-release evidence.

Go live in 48 hours.